Wells Fargo & Company Issues Positive Forecast for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its target price lifted by investment analysts at Wells Fargo & Company from $87.00 to $110.00 in a note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target points to a potential upside of 23.32% from the company’s current price.

A number of other analysts have also recently commented on KNSA. Wedbush lifted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Wall Street Zen downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 12th. Zacks Research lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. Weiss Ratings raised Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Finally, The Goldman Sachs Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Eight research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $96.43.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA opened at $89.20 on Wednesday. Kiniksa Pharmaceuticals International has a twelve month low of $35.20 and a twelve month high of $90.80. The firm’s 50-day moving average is $78.23 and its two-hundred day moving average is $59.23.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to analyst estimates of $260.66 million. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International will post 1.37 earnings per share for the current year.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CAO Michael Megna sold 4,600 shares of the stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the transaction, the chief accounting officer directly owned 29,062 shares of the company’s stock, valued at approximately $2,333,678.60. This trade represents a 13.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 51.98% of the company’s stock.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently bought and sold shares of KNSA. Curry Webb Wealth Management LLC acquired a new stake in Kiniksa Pharmaceuticals International during the third quarter valued at approximately $29,000. Allworth Financial LP boosted its holdings in Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock worth $29,000 after buying an additional 134 shares in the last quarter. Nykredit A S acquired a new position in Kiniksa Pharmaceuticals International in the second quarter worth approximately $34,000. KBC Group NV acquired a new position in Kiniksa Pharmaceuticals International in the first quarter worth approximately $34,000. Finally, USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International in the third quarter worth approximately $69,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Kiniksa Pharmaceuticals International

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Quarterly results exceeded expectations. Kiniksa reported third-quarter adjusted earnings of $0.56 per share, up from $0.23 a year earlier and above analyst estimates of approximately $0.32-$0.37. Revenue reached $285.97 million, surpassing the roughly $260.66 million consensus estimate. Kiniksa Pharmaceuticals International Reports Third-Quarter and Nine-Month Earnings
• Positive Sentiment: ARCALYST sales continued to accelerate. Net product revenue rose approximately 58% year over year to $286 million. The company said ARCALYST penetration among patients with multiple recurrences of pericarditis reached 23%, indicating additional room for growth in the core market. Kiniksa Pharmaceuticals: Three Key Takeaways for Long-Term Investors
• Positive Sentiment: Management raised its 2026 outlook. Expected ARCALYST revenue was increased to $1.045 billion-$1.050 billion, or more than $1.045 billion, reinforcing expectations for continued commercial momentum. Kiniksa Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Pipeline progress adds longer-term potential. Kiniksa expects pivotal Phase 3 data for KPL-387 in the second half of 2027, offering a future catalyst beyond ARCALYST’s current growth. Kiniksa Q3 2026 Earnings Call Transcript
• Neutral Sentiment: Short-interest data showed no reported short position. A report listed October short interest at zero shares and a zero-day days-to-cover ratio. While this does not indicate active bearish positioning, the figure may reflect incomplete or unusual data rather than a meaningful fundamental development.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.